BioCentury
ARTICLE | Clinical News

Pain shifting to AD following fourth Remoxy CRL

August 10, 2018 6:11 AM UTC

Pain Therapeutics Inc. (NASDAQ:PTIE) fell $1.11 (47%) to $1.25 on Aug. 6 after receiving its fourth complete response letter from FDA for pain candidate Remoxy ER oxycodone extended release (PF-00345439). The company does not plan to further develop Remoxy and will reorganize to shift its focus to Alzheimer's disease.

The NDA was seeking approval of Remoxy to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate...

BCIQ Target Profiles

Filamin A (FLNA)